Denosumab for Type 1 Diabetes
Phase 1/2
45
about 3.1 years
18–50
3 sites in AL, CA, IN
What this study is about
This trial is testing whether denosumab, a medication approved to treat osteoporosis and bone cancer, can protect beta cells in people with early type 1 diabetes. The goal is to determine if denosumab improves beta cell function and blood sugar control.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take Denosumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
denosumab
injection, subcutaneous
Primary: Primary efficacy endpoint, Primary safety endpoint
Secondary: HbA1c improvement
Endocrinology